Monthly Archives: March 2007

A Big Win for Prostate Cancer

30
Mar 07
After yesterday’s FDA Advisory Committee vote 13 to 4 to approve Provenge, and 17 to 0 on the safety issue, I told you to expect Dendreon (DNDN) shares to be up sharply today. And they were definitely up, spiking as high as $18 this morning. The spike is because there is a large short interest in the stock. I’ve reviewed some of the analyst recommendations by those who were negative on the stock, and they are clinging to the idea that the FDA will only issue an approvable letter, requiring the company to finish its current Phase III trial to...

Read More »

Bet on the Underdog

29
Mar 07
It seems to be an American trait to cheer for the underdog, and I like a David-versus-Goliath story as much as anyone. But I almost never bet real money on David, because that’s not the way the fight usually turns out. Though, in the case of Rochester Medical Corp. (ROCM), the subject of Monday’s Flash Alert, we get to enjoy the underdog story and make money, because the fight is over and David won. Wall Street just hasn’t noticed yet — not a single Street analyst follows the stock. To recap a bit and expand on the Flash Alert, Rochester...

Read More »

A New Biotech Buy

27
Mar 07
I’m always looking for great companies that fill a need in a sizable market. Today I’d like to tell you about a brand new company that fits all of these criteria and more. In fact, no Wall Street firms follow this stock, and I would normally just publish this recommendation in the Thursday issue, but yesterday, Forbes.com wrote the stock up, jumping it $1.45 on the opening. It slowly sold off for the rest of the day, but it is in the Top 25 of the Investor’s Business Daily Top 100, and it could have an explosive move any day...

Read More »

An Update on @Road’s Acquisition

23
Mar 07
@Road (ARDI) was acquired by Trimble Navigation (TRMB) last week for about $7.50 a share, of which $5.00 is in cash and the rest is 0.0447 shares of pre-split Trimble common stock for each outstanding share of ARDI common stock. TRMB split their stock 2-for-1 this week, so you will get 0.0894 of the new shares for each share of ARDI that you held. My near-term target on ARDI was $8.00, and even though ARDI sold out at $7.50, we still have almost a 98% gain. In light of this acquisition, many of you are probably wondering what to do...

Read More »

Our MegaShifts Buck the Trend

15
Mar 07
Tuesday’s drop, the second-biggest for the Dow Jones Industrial Average in four years, sent a clear message that the stock market has entered a more volatile time. Yesterday and today’s recoveries almost certainly are designed to suck more money into the market from those who think the “adjustment” is over. But the S&P 500 closed below the 1395 breakdown level, and it could rally all the way back to 1407 or even 1420 without convincing me that we are out of the woods. So, you should still be in the mode of letting the market tell you which way it’s...

Read More »

Hit Pause for a Minute and Take a Peek at the Content on Demand MegaShift

08
Mar 07
Even though I was looking for a big drop in the market before we really blast off on the two-year tech bull market that lies just ahead, last week was nerve-wracking. For now, the market seems to have stabilized. What that really means is the energy is balanced between buyers and sellers, and so far there is little indication of which short-term direction we will go next. But the range is pretty tight: Any substantial weakness in the S&P 500 under 1395 or strength over 1405 should tell the tale. So far, the bounce has been unimpressive if the bulls...

Read More »